Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Bio-Rad is a multinational developer and manufacturer of life science research and clinical diagnostics products. Operations are organized into two segments: Life Science and Clinical Diagnostics. The company sells over 12,000 products to scientific research, healthcare, education, and government customers globally.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Sales | $651.0 | $651.6 | $1,243.1 | $1,237.0 |
| Gross Profit | $345.8 | $345.3 | $655.2 | $651.3 |
| Gross Margin % | 53.1% | 53.0% | 52.7% | 52.7% |
| Operating Income | $72.6 | $77.1 | $106.7 | $100.8 |
| Net Income (Loss) | $371.4 | $317.8 | $(155.7) | $381.8 |
| Diluted EPS | $13.85 | $11.67 | $(5.80) | $13.84 |
| Operating Cash Flow (YTD) | $206.8 (2026) vs $246.4 (2025) | |||
| Total Debt (Carrying Value) | $1,203.7 (Current: $400.7; Long-term: $803.0) | |||
| Cash & Short-term Investments | $1,618.5 |
Material Changes vs. Prior Period
- Revenue: Q2 2026 net sales were essentially flat ($651.0M) compared to Q2 2025 ($651.6M). On a currency-neutral basis, sales decreased 1.9%. YTD sales increased 0.5% to $1.24B, but decreased 3.0% on a currency-neutral basis.
- Segment Performance:
- Life Science: Q2 sales decreased 4.1% ($252.0M) driven by challenges in the academic research market. YTD sales decreased 2.2%.
- Clinical Diagnostics: Q2 sales increased 2.6% ($399.0M) driven by growth in quality systems, diabetes, and blood typing products. YTD sales increased 2.3%.
- Non-Operating Volatility: Net income for Q2 2026 was significantly boosted by a $458.0M gain from changes in the fair market value of equity securities (primarily Sartorius AG) and loan receivables. Conversely, YTD 2026 reported a net loss of $155.7M due to a $280.2M loss in the same category, contrasting with a $366.2M gain in YTD 2025.
- Expenses: SG&A expenses increased to $212.0M in Q2 (32.6% of sales) due to higher employee costs. R&D expenses were $61.2M in Q2 (9.4% of sales). YTD R&D decreased to $124.1M due to lower restructuring costs.
Guidance, Outlook, Risks, and Unusual Items
- Restructuring Plan: On July 31, 2026 (subsequent to period end), the company initiated a strategy-driven restructuring plan. Estimated pre-tax charges are $80M to $90M, primarily for termination benefits. The plan is expected to be substantially completed by the end of fiscal year 2027.
- Geopolitical Risks: Escalation of regional conflicts in the Middle East has adversely affected demand and logistics in the EMEA region, particularly for Clinical Diagnostics. The company expects these conditions to continue through the remainder of 2026.
- Market Conditions: Ongoing challenges in the academic research market and uncertainty in the China market (mid-single digit % of sales) continue to limit growth opportunities. Government funding reductions and capital spending constraints remain a risk.
- Investment Volatility: The company holds a significant position in Sartorius AG (approx. 38% of ordinary shares). Changes in the market value of this position materially impact financial results independent of operating performance. Q2 2026 saw a $430.0M gain on this investment, while YTD 2026 saw a $297.7M loss.
- Liquidity: The company has $1.62B in cash, cash equivalents, and short-term investments. A $400M Senior Note matures in March 2027 (classified as current), but management asserts sufficient liquidity to repay.
Investor Verification Checklist
- Sartorius AG Valuation: Verify the current market price of Sartorius AG shares to understand the volatility in the "Gains/losses from change in fair market value" line item, which dominates net income/loss.
- Restructuring Impact: Monitor the Q3 2026 filing for the initial recognition of the $80M-$90M restructuring charges announced in July 2026.
- Currency Exposure: Review currency-neutral sales trends, as reported growth is often masked by favorable or unfavorable foreign exchange rates (61% of sales are international).
- Debt Maturity: Confirm the refinancing strategy or repayment plan for the $400M Senior Notes due in March 2027.
- Acquisition Integration: Review the final purchase price allocation for the Stilla Technologies acquisition, which was finalized in Q2 2026 with a $1.1M decrease in goodwill.